Bone morphogenic factor gene dosage abnormalities in prostatic intraepithelial neoplasia and prostate cancer.

Bone morphogenic factor gene dosage abnormalities in prostatic intraepithelial neoplasia and prostate cancer. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Bone morphogenic factor gene dosage abnormalities in prostatic intraepithelial neoplasia and prostate cancer. Abstract Text:

Shareen H Doak,Spencer A Jenkins,Rhidian A Hurle,Murali Varma,Azad Hawizy,Howard G Kynaston,James M Parry,

Abnormal expression of bone morphogenic proteins (BMP) has been reported in prostate cancer as compared to benign prostatic tissue. Since aberrations in gene expression often result from alterations in gene copy number, we have investigated this possibility in patients with early prostate cancer. Probes for fluorescence in situ hybridization for the BMP, BMP5, BMP7, and UC28 gene loci were developed and applied to archival sections with areas of adjacent benign epithelium, high-grade prostatic intraepithelial neoplasia, and prostate carcinoma. Two hundred nuclei from each region were evaluated. No deletions of the gene loci examined were observed, but gain of BMP2, BMP5, BMP7, and UC28 occurred in 58, 50, 50, and 67% of tumor foci, respectively. These aberrations in copy number may be caused by early events in tumor development because they were also present in 10-30% of high-grade prostatic intraepithelial hyperplasia foci. In addition, one tumor demonstrated a tandem amplification of the UC28 gene locus. Approximately half of the prostate tumors displayed increased copy numbers of the BMP2, BMP5, BMP7, and UC28 gene loci, which may account for their abnormal gene expression patterns in neoplastic prostate tissue.

Bone morphogenic factor gene dosage abnormalities in prostatic intraepithelial neoplasia and prostate cancer. Publishing Authors By Initials

SH Doak,SA Jenkins,RA Hurle,M Varma,A Hawizy,HG Kynaston,JM Parry,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Bone morphogenic factor gene dosage abnormalities in prostatic intraepithelial neoplasia and prostate cancer. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Cancer genetics and cytogenetics

VOLUME: 176

Page Numbers: 161-5

Journal Abbreviation: Cancer Genet. Cytogenet.

ISSN: 0165-4608

DAY: 15

MONTH: Jul

YEAR: 2007

Bone morphogenic factor gene dosage abnormalities in prostatic intraepithelial neoplasia and prostate cancer. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7909240

Bone morphogenic factor gene dosage abnormalities in prostatic intraepithelial neoplasia and prostate cancer. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Bone morphogenic factor gene dosage abnormalities in prostatic intraepithelial neoplasia and prostate cancer. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Bone morphogenic factor gene dosage abnormalities in prostatic intraepithelial neoplasia and prostate cancer.

AFFILIATION: School of Medicine, University of Wales Swansea, Singleton Park, Swansea SA2 8PP, Wales, UK.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Cancer Genet Cytogenet

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Bone morphogenic factor gene dosage abnormalities in prostatic intraepithelial neoplasia and prostate cancer Related Publications

• A case of nocturnal fainting: supine vasovagal syncope.
• Alopecia areata associated with refractive errors.
• Ascorbic acid content of some local Barbados foods.
• Bone morphogenic factor gene dosage abnormalities in prostatic intraepithelial neoplasia and prostate cancer.
• Breast abscess caused by Propionibacterium avidum following breast reduction surgery: case report and review of the literature.
• CATARACT EXTRACTION IN REFRACTORY PATIENTS AND THE OPERATIVE TREATMENT OF IRIDO-DIALYSIS.
• Comparative evaluation of 15 serological assays for the detection of syphilis infection.
• Discoveries in Rubisco (Ribulose 1,5-bisphosphate carboxylase/oxygenase): a historical perspective.
• Epileptic states in the dog, with special reference to canine-hysteria.
• Genetic and agronomic approaches to decreasing acrylamide precursors in crop plants.
• Hepatitis B vaccine uptake among injecting drug users in England 1998 to 2004: is the prison vaccination programme driving recent improvements?
• Hepatitis C virus (HCV) prevalence, and injecting risk behaviour in multiple sites in England in 2004.
• Modern therapeutic agents.
• Modern therapeutic agents.
• OC40: A comparison of 2D and 3D ultrasound methods of assessing fetal fat in growth abnormalities using customised birth weight outcomes.
• POST-OPERATIVE SECURITY IN CATARACT CASES.
• POST-OPERATIVE SECURITY IN CATARACT CASES.
• Perceived shifts in saturation and hue of chromatic stimuli in the near peripheral retina.
• Perimenopausal depression.
• Post-operative security in cataract operation.
• Serological testing algorithm shows rising HIV incidence in a UK cohort of men who have sex with men: 10 years application.
• Sleep disturbances at menopause are related to sleep disorders and anxiety symptoms.
• Substance abuse intervention in South Africa.
• Tasks ahead in public health.
• The amount of nicotine absorbed in smoking.
• The effect of hepatectomy on the action of certain anaesthetics in rats.
• The effect of paludrine on gastric secretion in man.
• The place and scope of the health centre in the health services of the future.
• The structure of whale blubber, and a discussion of its thermal properties.
• Use of single-value protein compensation of the jaffe creatinine assay contributes to clinically significant inaccuracy in results.